Acceleron to Host Research and Development Day on September 19, 2017
12 Septiembre 2017 - 6:00AM
Business Wire
- Acceleron’s senior management team and
external experts to present clinical development programs and
preclinical research efforts -
- Live conference call and webcast scheduled
for 8:00 a.m. EDT on September 19th –
Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will
webcast a live presentation from its Research and Development
(R&D) Day on Tuesday, September 19, 2017. The event will
take place from 8:00 a.m. to 12:00 p.m. EDT in New York City.
Members of the Acceleron leadership team will discuss the
R&D strategy, long-term vision for the Company, and its
clinical development programs across a range of disease areas,
including neuromuscular disease and hematology. External experts,
along with Acceleron, will provide insight into the current
treatment of myelodysplastic syndromes (MDS), beta-thalassemia, and
neuromuscular diseases. The Company will also present its latest
preclinical research in a new therapeutic area of interest.
Guest external speakers include:
- Maria Domenica Cappellini, M.D.,
Director of the Department of Clinical Sciences, Director of the
Unit of Internal Medicine, University of Milan, Italy
- David Steensma, M.D., Senior Physician,
Dana-Farber Cancer Institute, Associate Professor of Medicine,
Harvard Medical School
- Martin Childers, D.O., Ph.D., Professor
of Rehabilitation Medicine, Co-Director, MDA Clinic, University of
Washington, Co-Director, Institute for Stem Cell and Regenerative
Medicine
Conference Call and Webcast
The live webcast will be accessible under "Events &
Presentations" in the Investors/Media page of the Company's website
at www.acceleronpharma.com.
Individuals can participate in the conference call by dialing
877-312-5848 (domestic) or
253-237-1155 (international) and refer to "Acceleron
2017 R&D Day."
The archived webcast will be available for replay on the
Acceleron website approximately two hours after the event.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of innovative
therapeutics to treat serious and rare diseases. Its pioneering
research platform leverages the powerful biology behind the body's
ability to rebuild and repair its own cells and tissues. The
Company's lead therapeutic candidate, luspatercept, is being
evaluated in Phase 3 studies for the treatment of the hematologic
diseases myelodysplastic syndromes (MDS) and beta-thalassemia under
a global partnership with Celgene. Acceleron is also advancing its
ACE-083 clinical program in the field of neuromuscular disease, and
has a comprehensive preclinical research effort targeting fibrotic
and other serious diseases.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social
Media: @AcceleronPharma and LinkedIn.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170912005691/en/
Acceleron Pharma Inc.Todd James, IRC, 617-649-9393Vice
President, Investor Relations and Corporate CommunicationsorCandice
Ellis, 617-649-9226Manager, Investor Relations and Corporate
CommunicationsorMedia:BMC CommunicationsBrad Miles,
646-513-3125
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024